Should anti-Helicobacter therapy be different in patients with dyspepsia compared with patients with peptic ulcer diathesis?

European Journal of Gastroenterology and Hepatology

Volumn 13, Issue 11, 2001, Pages 1281-1284

  De Boer, Wink A ^a   Tytgat, Guido N J ^b  

^a BERNHOVEN HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Functional dyspepsia; Helicobacter pylori; Non ulcer dyspepsia; Peptic ulcer; Proton pump inhibitor; Ranitidine bismuth citrate; Treatment

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE;

ANTIBIOTIC THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DYSPEPSIA; ERADICATION THERAPY; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; META ANALYSIS; PATIENT SELECTION; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; STOMACH MUCOSA; STRAIN DIFFERENCE; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTI-ULCER AGENTS; DYSPEPSIA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER; PROTON PUMPS; RANITIDINE;

EID: 0035201429     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200111000-00002     Document Type: Review

References (46)

1. Disease management in ulcer disease
2. Search and treat strategy to eliminate Helicobacter pylori associated ulcer disease
3. Cost-effectiveness of H. pylori eradication regimens: Efficacy vs effectiveness
4. Strategies for therapy failures: Choice of 'back-up' regimen determined by primary treatment for Helicobacter pylori infection
5. Clinical review. Treatment of Helicobacter pylori infection
6. How to treat H. pylori infection. Should treatment strategies be based on testing bacterial susceptibility? A personal viewpoint
7. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication
8. Costs of diagnosis and treatment of Helicobacter pylori infection: When does choosing the treatment regimen based on susceptibility testing become cost-effective?
9. Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia
10. Spiramycin is comparable to oxytetracycline in eradicating H. pylori when given with ranitidine bismuth citrate and metronidazole
11. A multicentre study on eradication of Helicobacter pylori using four 1-week triple therapies in China
12. Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success
13. Significant increase in eradication rates of Helicobacter pylori infection with two consecutive dual therapies (omeprazole and amoxycillin or omeprazole and clarithromycin). A randomized study in 450 Spanish patients
14. Outcome of omeprazole-based dual and triple therapy for Helicobacter pylori eradication: Do gastroduodenal disease and age play a role?
15. Triple therapy omeprazole + amoxycillin + clarithromycin for Helicobacter pylori infection. 6 vs 12 days. Results and cost analysis
16. Helicobacter pylori eradication: Duodenal ulcer vs functional dyspepsia
17. Weekend therapy for the treatment of Helicobacter pylori infection
18. Factors influencing the eradication of Helicobacter pylori with triple therapy
19. One week triple therapy for Heilcobacter pylori: A multicentre comparative study
20. Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori
21. Helicobacter pylori eradication with lansoprazole, amoxycillin and clarithromycin: Testing an ideal regimen in a multicultural south east Asian population and examining factors potentially influencing eradication
22. The impact of clinical factors on the outcome of a new short term H. pylori eradication scheme
23. Activity and severity of gastritis and Helicobacter load do not influence the outcome of OAC-10
24. Prevalence of peptic ulcer bleeding by eradication of Helicobacter pylori infection
25. Patient factors affecting Helicobacter pylori eradication with triple therapy
26. Factors affecting the variation in antibiotic resistance of Helicobacter pylori over a 3-year period
27. H. pylori in vitro susceptibility to antibiotics in Portugal - A multicentre study
28. Review article. Treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies
29. Effect of Helicobacter pylori eradication on gastritis in relation to cagA: A prospective 1-year follow-up study
30. Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment
31. Cag negative status: A risk factor for failure of Helicobacter pylori triple therapies in non-ulcer dyspepsia
32. The efficacy of laboratory diagnosis of Helicobacter pylori infection in gastric biopsy specimens is related to bacterial density and vacA, cagA and iceA genotypes
33. High Helicobacter pylori numbers are associated with low eradication rate after triple therapy
34. Bacterial density of Helicobacter pylori predicts the success of triple therapy in bleeding duodenal ulcer
35. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy?
36. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori
37. Helicobacter pylori cytotoxic genotype is associated with peptic ulcer and influences serology
38. The significance of cagA and vacA subtypes of Helicobacter pylori in the pathogenesis of inflammation and peptic ulceration
39. Augmented levels of gastric mucosal leucocyte activation by infection with cagA gene-positive Helicobacter pylori
40. Is there any difference in Helicobacter pylori eradication rates in patients with active peptic ulcer, inactive peptic ulcer and functional dyspepsia?
41. Helicobacter pylori vacA genotypes and cagA gene in a series of 383 H. pylori positive patients
42. Clinical relevance of the cagA, vacA and iceA status of Helicobacter pylori
43. Helicobacter pylori genotypes are associated with clinical outcome in Portuguese patients and show a high prevalence of infections with multiple strains
44. Treatment failures and secondary resistance to antibiotics. A growing concern in Helicobacter pylori therapy
45. Association between vacA and cagA status and the efficacy of a 1-day quadruple therapy
46. A metaanalysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection